Metsera, Inc.

Metsera, Inc. (MTSR) priced its initial public offering on Jan 31, 2025 at $18.00 per share, above its $15.00–$17.00 range, raising $275M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.85B. BofA Securities was lead-left underwriter, joined by Goldman Sachs, Evercore ISI and Guggenheim and others. Latham & Watkins advised the company and Goodwin Procter advised the underwriters.

Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions, which it describes as among the most prevalent chronic human conditions.

Status

IPO

Ticker

MTSR

Exchange

Nasdaq Global Select

Priced

Jan 31, 2025

IPO price

$18.00

Price range

$15.00–$17.00

Raised

$275M

Market cap at IPO price

$1.85B

First filed

Jan 10, 2025

Underwriters

BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim and Cantor

Company counsel

Latham & Watkins

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.